OMALIZUMAB: SEVERE ALLERGIC ASTHMA TREATMENT OPTION

Abstract

Omalizumab is a monoclonal antibody against immunoglobulin E (IgE) which prevents free IgE from interacting with the high and low affinity IgE receptors on effector cells. Results of various studies proved that omalizumab improves asthma control, reduces exacerbations, corticosteroids use and have the potential to reduce airway remodeling. Moreover, effectiveness of omalizumab is similar in high and low eosinophil subgroups. The clinical efficacy and safety of omalizumab are documented in many clinical trials.